| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Concentration | |
| Conjugate | |
| Host | |
| Immunogen | Recombinant Human Breast cancer type 2 susceptibility protein |
| Isotype | |
| Product Type | |
| Shipping | |
| Storage | |
| UniProt # |
Product Overview
Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.
Validated Applications & Recommended Dilutions
| Application | Recommended Dilution |
|---|---|
| WB | 1:1000-1:3000 |
| IHC | 1:100-1:200 |
| IF | 1:100-1:400 |
Antibody Specifications
| Target | BRCA2 |
|---|---|
| Host Species | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Purification | Antigen Affinity Purification |
| Concentration | 1 mg/mL |
| Molecular Weight | Calculated 384 kDa; Observed 384 kDa |
Immunogen
Recombinant Human Breast cancer type 2 susceptibility protein UniProt: P51587.
Species Reactivity & Cross-Reactivity
Validated for: Human, Rat. Verify suitability in your sample type prior to use. For species or applications not listed in the datasheet, consult our technical team before purchase.
Storage & Handling
Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.
Storage Buffer: PBS with 0.02% sodium azide,1% protective protein and 50% glycerol,pH7.4
Related Products
Browse additional antibodies targeting BRCA2 and complementary reagents — including secondary antibodies, blocking buffers, and detection kits — available through BioHippo.
The recommended starting dilution for Western Blot is WB 1:1000-1:3000;IHC 1:100-1:200;IF 1:100-1:400. Optimal dilution should be determined empirically for each laboratory setup, sample type, and detection system. Use freshly prepared lysates with protease inhibitors; add phosphatase inhibitors if studying phosphorylation-dependent forms of BRCA2. Expected band size: Calculated 384 kDa, Observed 384 kDa. If background is high, increase blocking (5% non-fat milk or BSA in TBST) and/or increase wash stringency.
For IHC-P, heat-induced epitope retrieval (HIER) is typically required. Recommended starting conditions: citrate buffer pH 6.0 (microwave or pressure cooker, ~20 min) for rodent samples; EDTA buffer pH 9.0 for human clinical samples. After retrieval, allow sections to cool gradually before proceeding to blocking. Include a BRCA2-positive tissue control (confirmed by literature or database expression data) and a negative isotype control in every run. Recommended dilution: WB 1:1000-1:3000;IHC 1:100-1:200;IF 1:100-1:400. Refer to the product datasheet for any target-specific retrieval guidance.
For intracellular targets including most nuclear and cytoplasmic proteins, fix cells with 4% paraformaldehyde (15 min, room temperature) followed by permeabilization with 0.1–0.2% Triton X-100 or saponin (5–10 min). For surface membrane targets, fixation without permeabilization may be sufficient. Block with 5–10% normal serum (matching the secondary antibody host species) for 30–60 min. Incubate primary antibody at the recommended dilution (WB 1:1000-1:3000;IHC 1:100-1:200;IF 1:100-1:400) at 4°C overnight or 1–2 h at room temperature. Confirm nuclear/cytoplasmic localization of BRCA2 against published protein databases before designing your protocol.
This antibody has been experimentally validated in: Human, Rat. Cross-reactivity with other species has not been systematically evaluated. If your sample species is not listed, assess immunogen sequence homology to your target species ortholog. The immunogen used is: "Recombinant Human Breast cancer type 2 susceptibility protein" — higher sequence identity between species increases the probability of cross-reactivity, but experimental validation with appropriate controls is necessary before drawing scientific conclusions.
Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles. Storage Buffer: PBS with 0.02% sodium azide,1% protective protein and 50% glycerol,pH7.4. To maintain antibody activity, avoid repeated freeze-thaw cycles. Aliquot into single-use volumes before first freeze. If working with the antibody frequently, keep a working stock at 4°C for up to 4 weeks — add 0.02% sodium azide to the working stock as a bacteriostatic agent if azide is not already present in the buffer. Monitor performance against a validated positive control when transitioning between storage aliquots or lots.
Polyclonal antibodies are produced from immunized animals and may exhibit some degree of lot-to-lot variation in titer, background, and sensitivity. Each production lot is tested for performance against established acceptance criteria. When transitioning to a new lot, run a side-by-side pilot comparison against your previous lot using a validated positive control sample before updating your standard protocol. If significant performance differences are observed, contact our technical support team — titer adjustments may resolve the issue in most cases.
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
